Successful resolution of acute myelogenous leukemia-associated hemophagocytic lymphohistiocytosis with decitabine

Mulay, Sudhanshu; Bauer, Frank; Boruchov, Adam; Bilgrami, Syed

doi:10.3109/10428194.2010.534209

Cited by 5 publications

(5 citation statements)

References 14 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a previous report about an MDS patient with HLH, the administration of corticosteroids and subsequent induction chemotherapy did not lead to improvement ( 16 ). The effectiveness of decitabine for HLH associated with AML was reported previously ( 7 ). Decitabine is a hypo-methylating agent used for the treatment of high-risk MDS and AML ( 22 ).…”

Section: Discussionsupporting

confidence: 52%

“…Decitabine has been reported to be effective against acute myeloid leukemia (AML)-associated HLH ( 7 ); we therefore administered azacitidine (75 mg per square meter of body-surface area on 7 consecutive days every 4 weeks) at 1 month after the second corticosteroid treatment. The serum AST, ALT, and LDH levels started to decrease within 10 days, and pancytopenia and hyperferritinemia improved after one cycle of azacitidine.…”

Section: Case Reportmentioning

confidence: 99%

See 1 more Smart Citation

Successful Treatment of Hemophagocytic Lymphohistiocytosis Associated with Low-risk Myelodysplastic Syndrome by Azacitidine

et al. 2018

View full text Add to dashboard Cite

Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening syndrome that occurs as a complication in many clinical settings. Malignancy-associated HLH develops in patients with hematopoietic neoplasms, particularly in those with lymphoma, and its development in those with myelodysplastic syndrome (MDS) is uncommon. We herein report a case of HLH in a patient with low-risk MDS that was successfully treated with azacitidine. The prevalence of immune abnormalities among MDS patients and the immune effects of azacitidine have recently been elucidated, suggesting that MDS-associated HLH occurs as a result of immune impairment, and azacitidine improves this condition by restoring the immune system.

show abstract

Section: Discussionsupporting

confidence: 52%

Section: Case Reportmentioning

confidence: 99%

Successful Treatment of Hemophagocytic Lymphohistiocytosis Associated with Low-risk Myelodysplastic Syndrome by Azacitidine

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In total, 11 cases of AML associated with HPS have been reported in the English language literature (8,(11)(12)(13)(14)(15)(16)(17)(18)(19)(20). Among these, only three cases presented HPS simultaneously at the initial diagnosis of AML as observed in the present case (Table 1) (8,11,20): all four cases were older Asian males who were diagnosed as having AEL with splenomegaly and unfavorable prognoses.…”

Section: Discussionmentioning

confidence: 51%

“…Secondary HPS is often caused by infections, autoimmune diseases, or malignant neoplasms (10). Most malignancies with HPS are T/NK-cell and B-cell lymphomas, whereas myeloid malignancies with HPS have been rarely reported (8,(11)(12)(13)(14)(15)(16)(17)(18)(19)(20). Here, we describe an unusual case of therapy-related PEL associated with HPS.…”

Section: Introductionmentioning

confidence: 94%

Therapy-Related Pure Erythroid Leukemia with Hepatic Infiltration and Hemophagocytic Syndrome

et al. 2011

View full text Add to dashboard Cite

Pure erythroid leukemia (PEL) is an extremely rare disorder characterized by neoplastic proliferation of immature erythroblasts. A 66-year-old man, who had received chemoradiotherapy for hypopharyngeal cancer, was admitted because of pancytopenia. Bone marrow was infiltrated with 81% proerythroblasts positive for CD71 and CD235a. An increased number of macrophages with active hemophagocytosis was also present. Chromosome analysis showed hypodiploid complex abnormalities. The patient died of progressive disease despite induction chemotherapy. Erythroblastic infiltration into the liver and hemophagocytosis in the spleen were found at autopsy. Therapy-related PEL with hemophagocytic syndrome and hepatic infiltration of PEL has never been reported.

show abstract

“…The latter is particularly related to the Epstein-Barr virus (EBV) and can develop a clinical pattern similar to that of HLH. In addition, the occurrence of HLH has been reported in various blood diseases such as multiple myeloma, acute leukemia, and chronic leukemia [26][27][28], and it can also occur with some solid cancers.…”

Section: Initiating Factorsmentioning

confidence: 99%

Current status of the diagnosis and treatment of hemophagocytic lymphohistiocytosis in adults

Kim

2021

Blood Res

View full text Add to dashboard Cite

Hemophagocytic lymphohistiocytosis (HLH) is a syndrome of defective apoptosis, a disruption of the regulatory pathway that terminates immune and inflammatory responses. Fever, cytopenia, splenomegaly, and/or hemophagocytosis are typical findings of this syndrome. HLH can be induced by genetic disorders (familial) or secondary causes. Familial HLH is rare, while secondary causes in adults include infection, autoimmunity, and malignancy. HLH in adults tends to be confused with or misdiagnosed as sepsis, mainly due to similar clinical manifestations and laboratory findings, which make it difficult to diagnose HLH rapidly and adopt immunosuppressive agents and/or chemotherapy adequately. Treatment of pediatric HLH using HLH-2004 or multi-agent chemotherapy can be applied in adult patients, although the dose and type of drug need to be adjusted. It is highly recommended that allogenic hematopoietic stem cell transplantation should be used in patients who become reactivated or are refractory to the initial treatment as soon as possible to improve survival. Future clinical trials are warranted to determine more suitable treatments for adult patients with HLH.

show abstract

Successful resolution of acute myelogenous leukemia-associated hemophagocytic lymphohistiocytosis with decitabine

Cited by 5 publications

References 14 publications

Successful Treatment of Hemophagocytic Lymphohistiocytosis Associated with Low-risk Myelodysplastic Syndrome by Azacitidine

Successful Treatment of Hemophagocytic Lymphohistiocytosis Associated with Low-risk Myelodysplastic Syndrome by Azacitidine

Therapy-Related Pure Erythroid Leukemia with Hepatic Infiltration and Hemophagocytic Syndrome

Current status of the diagnosis and treatment of hemophagocytic lymphohistiocytosis in adults

Contact Info

Product

Resources

About